{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:35:00Z","timestamp":1790440500992,"version":"4.1.0"},"reference-count":9,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2021,5,31]]},"DOI":"10.5582\/irdr.2021.01038","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T22:06:37Z","timestamp":1616537197000},"page":"146-147","source":"Crossref","is-referenced-by-count":3,"title":["Orphan drugs in different countries and development of new drugs to treat biliary tract cancer"],"prefix":"10.5582","volume":"10","author":[{"given":"Haihong","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Biliary and Pancreatic Surgery, Shanghai Shuguang Hospital Affiliated to Shanghai University of T.C.M., Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China."},{"name":"Shanghai Institute for Pediatric Research, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Valle JW, Kelley RK, Nervi B, Oh D-Y, Zhu AX. Biliary tract cancer. The Lancet. 2021; 397:428-444.","DOI":"10.1016\/S0140-6736(21)00153-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wang Y, Chen D, He J. A brief introduction to China&apos;s new Drug Administration Law and its impact on medications for rare diseases. Intractable Rare Dis Res. 2019; 8:226-230.","DOI":"10.5582\/irdr.2019.01133"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Alvarez-Argote J, Dasanu CA. Durvalumab in cancer medicine: a comprehensive review. Expert Opin Biol Ther. 2019; 19:927-935.","DOI":"10.1080\/14712598.2019.1635115"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Antonia SJ, Villegas A, Daniel D, <i>et al<\/i>. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379:2342-2350.","DOI":"10.1056\/NEJMoa1809697"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gray JE, Villegas A, Daniel D, <i>et al<\/i>. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. J Thorac Oncol. 2020; 15:288-293.","DOI":"10.1016\/j.jtho.2019.10.002"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Paz-Ares L, Dvorkin M, Chen Y, <i>et al<\/i>. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. The Lancet. 2019; 394:1929-1939.","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hoy SM. Pemigatinib: First Approval. Drugs. 2020; 80:923-929.","DOI":"10.1007\/s40265-020-01330-y"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Abou-Alfa GK, Sahai V, Hollebecque A, <i>et al<\/i>. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020; 21:671-684.","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Romero D. Benefit from pemigatinib in cholangiocarcinoma. Nat Rev Clin Oncol. 2020; 17:337.","DOI":"10.1038\/s41571-020-0369-z"}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/10\/2\/10_2021.01038\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T03:07:18Z","timestamp":1622862438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/10\/2\/10_2021.01038\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2021.01038","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,31]]}}}